Both Sides of the Fight

Empowering the Immune System to Prevent and Treat Disease

happy family

A Pipeline Grounded in Immunology

VBI’s pipeline is comprised of vaccine and immunotherapeutic candidates developed by virus-like particle technologies to target two distinct, but often related, disease areas – infectious disease and oncology.

We prioritize the development of candidates for disease targets that are challenging, underserved, and where the human immune system, when powered and stimulated appropriately, can be a formidable opponent.

Our pipeline is unified in the mission to achieve better health for all.

Icon
Prophylactic Candidates
Disease
Program
Technology
Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Hepatitis B (HBV)
    3-Antigen Vaccine
    VLP
  • Cytomegalovirus (CMV)
    VBI-1501
    eVLP
  • COVID-19
    VBI-2902
    eVLP
  • COVID-19
    (B.1.351 Variant)
    VBI-2905
    eVLP
  • Coronaviruses
    VBI-2901
    eVLP
  • Coronaviruses
    Undisclosed
    eVLP
  • Zika
    VBI-2501
    eVLP
Icon
Therapeutic Candidates
Disease
Program
Technology
Preclinical Phase 1 Phase 2 Phase 3 Approved
  • Hepatitis B (HBV)
    VBI-2601 (BRII-179)
    VLP
  • Glioblastoma (GBM)
    VBI-1901
    eVLP
  • Other CMV+ Tumors
    Undisclosed
    eVLP

Clinical Trials

Learn more about our ongoing and completed clinical studies of investigational vaccine candidates.

View NowArrow
people working

Publications

Browse our library of publications to read more about our science and pipeline candidates.

View NowArrow
Go top